



Dr. Boris Gorin joins Eurofins Alphora as Senior Scientific Advisor

Eurofins Alphora is pleased to announce that Dr. Boris Gorin has joined the management team in the role of Senior Scientific Advisor to support the company's continued growth in the range of developmental services for complex small molecules.



In this role, Dr. Gorin will provide leadership and guidance to assist technical teams innovate solutions to challenging chemical steps in the development and scale-up from bench to manufacturing plant through product development. With over 30 years of international experience in synthetic organic chemistry and process development and product commercialization for the pharmaceutical industry, and the author of over 50 patents and scientific publications, Dr. Gorin is well poised to provide scientific expertise to the technical teams at Eurofins Alphora.

Having held progressively senior roles in a number of leading companies serving the pharmaceutical and biotechnology companies such as, Raylo Chemicals, Alphora Research, and Apotex Pharmachem, Dr. Gorin has developed new synthetic processes for over one hundred new drug candidates, including various classes of natural products, heterocycles and phosphoroorganic compounds. Of these, several APIs were successfully launched to the pharmaceutical market. During his successive roles at Alphora Research from Research Manager to Vice President, Research and Development, he advanced a talented R&D department from a small start-up to a recognized CRO/CMO with niche expertise. He was also successful in the introduction of new technologies such as High-Throughput-Screening, Continuous Flow Processes, Process Analytical Technology, and others to API process development and optimization.

Eurofins Alphora provides API technology services for the scale-up of complex small molecule for pharmaceutical and biotechnology companies. The company supports IND and Commercial Readiness of APIs.

Alphora operates FDA and Health Canada inspected and approved facilities including cGMP manufacturing operations, organic chemistry PR&D and analytical laboratories supported by Quality Control/Quality Assurance functions. A separate high-potency suite completes Alphora's 74,000ft² facilities. A 3rd manufacturing plant is under construction and will come online early 2019 to add additional capacity for an active pipeline of projects.

For additional information on this news release or about Eurofins Alphora, please contact:

Rav Mahal, Ph.D. Vice President, Business Development and Project Management

E-mail: rav.mahal@alphoraresearch.com, or: info@alphoraresearch.com

2395 Speakman Drive, Suite 2001, Mississauga, Ontario, Canada L5K 1B3 Tel: 905 403-0477 alphoraresearch.com

